FDA adcom documents may offer reasonable path for OIC drug class
The FDA's Anesthetic and Analgesic Drug Products Advisory Committee (adcom) is slated to meet Wednesday to discuss the potential cardiovascular (CV) risk associated with peripherally acting opioid receptor antagonists in development to treat opioid-induced constipation (OIC).
Suite: 1100 | Atlanta, Georgia 30346, USA
Outside of the US
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
Sign up for Highlights FREE e-mail newsletter